Clinical Trial: A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Lung Cancer
Study Type: INTERVENTIONAL
Official Title: A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)
Brief Summary:
NSCLC patients with low expression level of PD-L1, esp.those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g.atezoilzumab).In this study, investigators hypothesize that the combination of cabozantinib (a multi-kinase inhibitor) and atezolizumab will result in better therapeutic value.
Read more